CODX
$2.29
Co-Diagnostics, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internat...
Recent News
Auna S.A. (AUNA) Tops Q4 Earnings and Revenue Estimates
Auna S.A. (AUNA) delivered earnings and revenue surprises of +324.00% and +1.92%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Community Health's $450M Hospital Divestment Reduce Debt Burden?
CYH plans to sell Crestwood Medical Center for $450M, a deal topping its market value and aimed at easing the hospital operator's heavy debt load.
Co-Diagnostics announces 1-for-30 reverse stock split
Co-Diagnostics (CODX) announced that it has filed a Certificate of Amendment to its Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio of 1-for-30 shares. The reverse stock split will become effective at 12:01 a.m. ET on Friday, January 2, 2026. Co-Dx’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “CODX” and will begin trading on a split-adjusted basis when the market opens on Friday, January 2, 2026. The reverse stock
CoDiagnostics (CODX) Upgraded to Buy: Here's What You Should Know
CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Co-Diagnostics Inc (CODX) Q3 2025 Earnings Call Highlights: Strategic Ventures and Financial ...
Co-Diagnostics Inc (CODX) explores new joint ventures and strategic alternatives amid revenue decline and financial restructuring.